A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Spondylarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 23 Oct 2017 Status changed from active, no longer recruiting to discontinued because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.
    • 11 Aug 2017 Planned End Date changed from 9 Dec 2019 to 1 Sep 2017.
    • 11 Aug 2017 Planned primary completion date changed from 10 Jan 2018 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top